Drug intelligence / Profile preview

CAR-T cell therapy (First Affiliated Hospital of Harbin Medical University)

Development stage: Unknown
Lead developer: The First Affiliated Hospital of Harbin Medical University
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

CAR-T cell therapy (First Affiliated Hospital of Harbin Medical University) is an investigational cell-based immunotherapy designed for the treatment of pancreatic cancer. This program utilizes T cells genetically engineered to express chimeric antigen receptors (CARs) that target specific tumor-associated antigens frequently overexpressed in pancreatic malignancies, including Mesothelin (MSLN), Prostate Stem Cell Antigen (PSCA), Carcinoembryonic Antigen (CEA), Human Epidermal Growth Factor Receptor 2 (HER2), Mucin 1 (MUC1), and Epidermal Growth Factor Receptor variant III (EGFRvIII). The therapy aims to harness the patient's immune system to recognize and destroy malignant cells overexpressing these markers. It is currently being evaluated in a Phase 1 clinical trial (NCT02706405) to determine its safety profile and therapeutic efficacy in patients with advanced or metastatic pancreatic cancer.

Other names: chimeric antigen receptor T cell-First Affiliated Hospital of Harbin Medical University-pancreatic cancerChimeric antigen receptor T cellCAR-T Immunotherapy for Pancreatic Cancer

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFRvIII (Epidermal growth factor receptor variant III)MUC1 (Mucin-1 Antigen)PSCA (Prostate stem cell antigen)Mesothelin

Beyond the preview

Go deeper on CAR-T cell therapy (First Affiliated Hospital of Harbin Medical University).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR-T cell therapy (First Affiliated Hospital of Harbin Medical University).

Explore the full profile